A

Aelis Farma SA
PAR:AELIS

Watchlist Manager
Aelis Farma SA
PAR:AELIS
Watchlist
Price: 2.88 EUR 2.13% Market Closed
Market Cap: 39.5m EUR
Have any thoughts about
Aelis Farma SA?
Write Note

Aelis Farma SA
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aelis Farma SA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
A
Aelis Farma SA
PAR:AELIS
Pre-Tax Income
-€5.1m
CAGR 3-Years
-19%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Pre-Tax Income
€20m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Pre-Tax Income
€22.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Pre-Tax Income
-€101.3m
CAGR 3-Years
-35%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Pre-Tax Income
€10m
CAGR 3-Years
-54%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
OSE Immunotherapeutics SA
PAR:OSE
Pre-Tax Income
€49.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aelis Farma SA
Glance View

Market Cap
35.9m EUR
Industry
Biotechnology

Aelis Farma SA develops biotechnology solutions. The company is headquartered in Bordeaux, Nouvelle-Aquitaine and currently employs 24 full-time employees. The company went IPO on 2022-02-18. The firm provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). The company offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. The company provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The firm operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.

AELIS Intrinsic Value
1.25 EUR
Overvaluation 57%
Intrinsic Value
Price
A

See Also

What is Aelis Farma SA's Pre-Tax Income?
Pre-Tax Income
-5.1m EUR

Based on the financial report for Dec 31, 2023, Aelis Farma SA's Pre-Tax Income amounts to -5.1m EUR.

What is Aelis Farma SA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-13%

Over the last year, the Pre-Tax Income growth was 64%. The average annual Pre-Tax Income growth rates for Aelis Farma SA have been -19% over the past three years , -13% over the past five years .

Back to Top